Share this article
TARRYTOWN, N.Y., May 17, 2021 /PRNewswire/
Patients treated with REGEN-COV had 4-day shorter duration of symptoms and significantly reduced viral load compared to placebo
Similar efficacy observed with both doses (1,200 mg and 2,400 mg); U.S. FDA is currently reviewing request to add lower 1,200 mg dose to EUA
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of detailed results from the Phase 3 pivotal trial showing REGEN–COV™ (casirivimab with imdevimab) significantly reduced the risk of hospitalization or death, shortened symptom duration and reduced viral load in non-hospitalized patients (outpatients) with COVID-19. These data were presented at the 2021 American Thoracic Society International Conference (ATS 2021) in the
Phase 3 Data Presented at ATS 2021 Show REGEN-COV™ (casirivimab with imdevimab) Reduced Risk of Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Published: Apr 12, 2021
TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/
REGEN-COV rapidly protected household contacts from exposure to SARS-CoV-2 at home, with 72% protection against symptomatic infections in the first week, and 93% in subsequent weeks
Among individuals who developed symptomatic infections, REGEN-COV recipients cleared the virus faster and had much shorter symptom duration
Regeneron will share data with U.S. FDA and request EUA expansion to include COVID prevention for appropriate populations, using a 1,200 mg subcutaneous dose
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 3 trial (2069A) assessing the ability of REGEN-COV™ (casirivimab with imdevimab) to reduce the risk and burden of COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (
Share this article
TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/
Second Phase 3 trial undertaken in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infection
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive data from a Phase 3 trial (2069B) of recently infected asymptomatic COVID-19 patients, evaluating REGEN-COV™ (casirivimab with imdevimab) 1,200 mg administered via subcutaneous (SC) administration. REGEN-COV reduced the overall risk of progressing to symptomatic COVID-19 by 31% (primary endpoint), and by 76% after the third day. The trial also demonstrated that REGEN-COV shortened symptom duration and markedly reduced viral levels.
The Phase 3 trial is the second to report results today, which was jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The trial enrolled
NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV™ (casirivimab with imdevimab) in Outpatients at High Risk of Clinical Progression prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.